Again, Rett Results Will Be Hard To Confine
Interesting the note in a posting below that girls being selected for the Rett trial have to display sufficient numbers of daily seizures to be enrolled.
That clearly reveals that seizure control or suppression is the target outcome of Anavex 2-73 in the upcoming 3-month trial.
Now, just how difficult will it be to quantify a reduction in seizure events in the girls in the study? Will blood have to be drawn and analyzed? Will electrodes have to be stuck on the girls and electromagnetic activity of the brain digitally charted and analyzed? Perhaps.
But, in fact, the mothers of every one of those little ladies will know in a day or two when, simply, their little girls lived a day or two without seizures. Useful assessment of Anavex 2-73 efficacy in seizure reduction in girls with Rett syndrome genomes will be rendered by motherly perceptions of the well-being status of their girls. Mothers know.
I'm not aware of the typical frequencies of seizures in Rett syndrome girls. But let's say it's once a day. How, then, will mothers react when they notice, say, in the fourth week of the trial, their girls went 7 days without a seizure? Will they think (as some here would), "Well, that's interesting. But who knows? Can't be that drug Little Susie is taking. Must be just chance. I'll keep quiet about this and won't say a thing until the trial is over. What could I know? I'm not a doctor."
No, Susie's mother will be telling all her friends that the drug is actually starting to work, that her girl now has the chance to live a normal life.
At that point, will anyone knowing of this post a message here, telling the whole world?
Let's see.
